Abstract
Background The plasmid-mediated bacterial colistin-resistant (mcr) gene is a global concern in clinical health care. This study aimed to clarify the prevalence of colistin resistance through nine mcr genes in ESBL-producing and CRE isolated Enterobacteriaceae in Japan.
Methods We collected strains from August 2016 to March 2017 from five tertiary hospitals. MICs were measured using the microdilution method. PCR was performed to detect mcr-1 to mcr-9 genes in all strains. Additionally, we performed whole-genome sequencing of the mcr gene-positive strain.
Results The rate of colistin resistance was 7.7%. The mcr-5 and mcr-9 gene were detected in one ESBL-producing E. coli strain (0.37%) and three CRE strains (1.1%), respectively. Since the ESBL-producing E. coli strain was the first clinical strain with mcr-5 in Japan, whole-genome sequencing analysis was performed for the strain. The sequenece type of the mcr-5 positive strain was ST1642 and it carried two distinct plasmids, ESBL gene-carrying pN-ES-6-1 and mcr-5.1-carrying pN-ES-6-2.
Conclusions We showed that the frequency of colistin resistance and mcr-positive strains is not high in Japan. Since the MIC for colistin was low in the mcr-5.1 and mcr-9 gene-positive strain, continuous monitoring of mcr genes is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific and the Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan (H28-Shinkou-Ippan-003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Nagasaki University Hospital (16072509). Data regarding clinical ESBL-producing Enterobacteriaceae and CRE isolates were anonymized and individually numbered when they were collected from the hospitals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data were generated at Nagasaki University Hospital. Derived data supporting the findings of this study are available from the corresponding author upon request.
